[go: up one dir, main page]

AR039843A1 - Tratamiento de padecimientos post-menopausicos en pacientes con cancer de mama - Google Patents

Tratamiento de padecimientos post-menopausicos en pacientes con cancer de mama

Info

Publication number
AR039843A1
AR039843A1 ARP030101779A ARP030101779A AR039843A1 AR 039843 A1 AR039843 A1 AR 039843A1 AR P030101779 A ARP030101779 A AR P030101779A AR P030101779 A ARP030101779 A AR P030101779A AR 039843 A1 AR039843 A1 AR 039843A1
Authority
AR
Argentina
Prior art keywords
patients
breast
cancer
menopausic
post
Prior art date
Application number
ARP030101779A
Other languages
English (en)
Inventor
Helenius Jan Kloosterboer
Anton Egbert Peter Adang
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of AR039843A1 publication Critical patent/AR039843A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Uso de tibolona y un SERM para fabricar una medicina para tratar una deficiencia de estrógeno relacionada con la enfermedad y para la prevención de una recurrencia de cáncer de mamas en las mujeres que sufren de cáncer de mama o que están en riesgo de ello que exhiben la deficiencia de estrógeno relacionada con la enfermedad. Reivindicación 2: Un uso de acuerdo a la reivindicación 1, caracterizado porque el SERM es tamoxifén. Reivindicación 3: Un uso de acuerdo a la reivindicación 1, caracterizado porque el SERM es raloxifeno.
ARP030101779A 2002-05-24 2003-05-22 Tratamiento de padecimientos post-menopausicos en pacientes con cancer de mama AR039843A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02077050 2002-05-24

Publications (1)

Publication Number Publication Date
AR039843A1 true AR039843A1 (es) 2005-03-02

Family

ID=29558370

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030101779A AR039843A1 (es) 2002-05-24 2003-05-22 Tratamiento de padecimientos post-menopausicos en pacientes con cancer de mama

Country Status (14)

Country Link
US (1) US20050222100A1 (es)
EP (1) EP1511497A1 (es)
JP (1) JP2005531575A (es)
KR (1) KR20050005490A (es)
CN (1) CN1655796A (es)
AR (1) AR039843A1 (es)
AU (1) AU2003273170A1 (es)
BR (1) BR0311146A (es)
CA (1) CA2487268A1 (es)
IL (1) IL165129A0 (es)
MX (1) MXPA04011687A (es)
PE (1) PE20031047A1 (es)
TW (1) TW200307553A (es)
WO (1) WO2003099292A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2234060A1 (en) * 1995-10-06 1997-04-10 Arch Development Corporation Methods and compositions for viral enhancement of cell killing
WO2007143607A2 (en) 2006-06-02 2007-12-13 Pear Tree Women's Health Care Method of treating atrophic vaginitis
US8933130B2 (en) 2006-06-23 2015-01-13 Radius Health, Inc. Treatment of vasomotor symptoms with selective estrogen receptor modulators
US20110124617A1 (en) * 2008-05-09 2011-05-26 Lyttle C Richard Combination Therapy for BreastCancer Comprising an Antiestrogenic Agent
DE102008057230A1 (de) * 2008-11-11 2010-05-12 Bayer Schering Pharma Aktiengesellschaft Synergistische pharmazeutische Kombination mit einem Estrogenrezeptorantagonisten und einem Progestin
MX342898B (es) 2010-05-12 2016-10-18 Radius Health Inc * Regimen terapéutico de la sal de diclorhidrato del (r) -6-(2-(etil (4-2(etilamino) etil) bencil) amino)-4-metoxifenil)-5, 6,7,8-tetrahidronaftaleno-2-ol.
ES2550319T3 (es) 2010-09-28 2015-11-06 Radius Health, Inc Moduladores selectivos del receptor de andrógenos
SI3122426T1 (sl) 2014-03-28 2023-04-28 Duke University Zdravljenje raka dojk z uporabo selektivnih modulatorjev estrogenskih receptorjev
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
IL255189B2 (en) 2015-04-29 2024-04-01 Radius Pharmaceuticals Inc A combination of rad1901 and a cdk4/6 inhibitor for use in treating cancer
CA3027563C (en) 2016-06-22 2024-07-02 Ellipses Pharma Ltd AR+ METHODS FOR BREAST CANCER TREATMENT
ES2981967T3 (es) 2017-01-05 2024-10-14 Radius Pharmaceuticals Inc Formas polimórficas de RAD1901-2HCl
WO2020010216A1 (en) 2018-07-04 2020-01-09 Radius Pharmaceuticals, Inc. Polymorphic forms of rad 1901-2hcl
PH12021551950A1 (en) 2019-02-12 2022-05-23 Radius Pharmaceuticals Inc Processes and compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK9592002A3 (en) * 2000-01-28 2003-12-02 Endorech Inc A method for reduction or elimination of the incidence of menopausal symptoms, method of treatment or decreasing the risk of an acquiring disease, a pharmaceutical composition and a kit
US6756480B2 (en) * 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
WO2003011282A1 (en) * 2001-07-31 2003-02-13 Pfizer Products Inc. Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists/antagonists, estrogens and progestins

Also Published As

Publication number Publication date
KR20050005490A (ko) 2005-01-13
CN1655796A (zh) 2005-08-17
AU2003273170A1 (en) 2003-12-12
WO2003099292A1 (en) 2003-12-04
TW200307553A (en) 2003-12-16
EP1511497A1 (en) 2005-03-09
PE20031047A1 (es) 2003-12-23
US20050222100A1 (en) 2005-10-06
JP2005531575A (ja) 2005-10-20
CA2487268A1 (en) 2003-12-04
MXPA04011687A (es) 2005-03-31
IL165129A0 (en) 2005-12-18
BR0311146A (pt) 2005-03-15

Similar Documents

Publication Publication Date Title
AR039843A1 (es) Tratamiento de padecimientos post-menopausicos en pacientes con cancer de mama
Schover Sexuality and body image in younger women with breast cancer
CL2007001724A1 (es) Uso de un estrogeno para el tratamiento de enfermedades, condiciones o sintomas asociados con niveles deficientes de estrogenos en una mujer; composicion farmaceutica que comprende unidades de dosificacion diarias de hemidrato de estradiol > 0,75 y 1
MX9700534A (es) Uso de droloxifeno y sus sales farmaceuticamente aceptables en la preparacion de remedios para tratar las enfermedades de prostata, endometriosis y obesidad.
DE60143857D1 (de) Zusammensetzung bestehend aus phy906 und chemotherapeutika
BRPI0608815A8 (pt) Composições de anticorpo anti-ctla-4
AR037109A1 (es) Uso de flibanserina
UY27455A1 (es) Derivados n-(1,4,5,6-tetrahidro-ciclopentapirazol -3-il)- sustituidos. su obtención y uso como fármacos.
GT200300294A (es) Compuestos de indazol y composiciones farmaceuticas para inhibir proteinquinasas y procedimientos para su uso
UY27939A1 (es) Compuestos
ES2189738T3 (es) Hidroximatairesinol en la prevencion del cancer.
NO20022065L (no) Terapeutisk anvendelse
BR0015992A (pt) Compostos, utilização dos mesmos, e, associações terapêuticas
PA8513101A1 (es) Derivados de eteres de pirazol como agentes anti- inflamatorios/analgesicos
BR0010702A (pt) Novas quinonas como terapias de doenças
ATE445389T1 (de) Liposomale glucocorticoide
UY26992A1 (es) Nuevas composiciones de medicamentos sobre la base de agentes anticolinérgicos y corticoesteroides
CY1108462T1 (el) Χρηση της αναστροζολης για τη θεραπευτικη αντιμετωπιση μετεμμηνοπαυσιακων γυναικων με καρκινο του μαστου σε πρωιμο σταδιο
PA8529701A1 (es) Compuestos retinoides
AR037343A1 (es) Uso de antagonistas del receptor de endotelina para la preparacion de un medicamento destinado al tratamiento de enfermedades tumorales
DK1328276T3 (da) Anvendelse af antiprogestiner til profylakse og behandling af hormonafhængige sygdomme
BR0312294A (pt) Arilcarbonil piperazinas e hteroarilcarbonilpiperazinas e o uso das mesmas para tratamento de doenças benignas e malignas
SE0300098D0 (sv) Use of cyclin D1 inhibitors
AR030140A1 (es) Composiciones derivadas de la 2-piridinamina y metodos relacionados
BR0113165A (pt) Derivados de 4-pirimidinamina, composições farmacêuticas e métodos relacionados

Legal Events

Date Code Title Description
FA Abandonment or withdrawal